How CluePoints Enabled Pfizer's 'Hyperspeed' Vaccine Development
Leveraging Risk-Based Quality Management to Facilitate Early Risk Detection
How CluePoints Detected Fraudulent Reporting of Investigational Product Administration from Patient Diary Data
Using CluePoints to Detect Anomalies in Electronic Patient-Reported Outcomes
Using CluePoints to Identify Severe Propagation in Vital Sign Measurements
Using CluePoints to Identify Fraud Due to the Fabrication of Patient Diaries
Using CluePoints to Detect Miscalibrated Equipment in a Clinical Trial
The Value of the CluePoints Solution in Identifying Under-reported Adverse Effects in a Clinical Trial
Using CluePoints to Reveal Protocol Deviations in Patient Selection
Conclusions from Executive Roundtable on Response to ICH E6 (R2)
Implementing a Scalable Risk-Based Monitoring Strategy
Sponsor Responses to the ICH E6 Revisions
The Principles of Central Statistical Monitoring
Got a Question?
Whether you’re looking to get started or need support, we’re here to help!
Featured Whitepaper
ICH E6 (R2)
Summary
Paper
Created in conjunction with our peers at TUFTS Center for the Study of Drug Development, this paper provides insights on how companies are responding to ICH E6 (R2) and information on the key themes on adoption.
Featured Webinar
ICH E6 (R2)
Webinar
Series
This recorded webinar covers all of the frequently asked Questions about ICH E6 (R2), Risk-Based Study Execution (RBx) and what’s required from a people, process & technology standpoint.
We're Kind of a Big Deal.
7,000
Platform Users
1,200
Studies De-Risked
100,000
Issues Detected